Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Inhaled corticosteroids and pneumonia mortality in COPD patients

Pere Almagro, Pablo Martinez-Camblor, Joan B. Soriano
European Respiratory Journal 2019 54: 1901035; DOI: 10.1183/13993003.01035-2019
Pere Almagro
1Multimorbidity Patients Unit, Internal Medicine Dept, University Hospital Mutua de Terrassa, University of Barcelona, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pere Almagro
  • For correspondence: 19908pam@comb.cat
Pablo Martinez-Camblor
2Geisel School of Medicine at Dartmouth, Hanover, NH, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joan B. Soriano
3Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid, Spain
4Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, Madrid, España
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joan B. Soriano
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chronic use of ICS increases the risk of pneumonia in COPD patients, although this risk is not homogenous. This study confirms that the risk of pneumonia-related mortality in randomised clinical trials is not increased in patients treated with ICS. http://bit.ly/2Zod6us

To the Editor:

In a recent article, Suissa [1] proposes several alternative hypotheses to explain the paradoxical effect of inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD) patients, whereby these drugs can increase the risk of pneumonia and simultaneously reduce pneumonia mortality. In our opinion, the conclusion of the article, that pneumonia mortality is increased in COPD patients treated with ICS, both in observational and in randomised clinical trials (RCTs), is not supported by data and cannot be considered confirmed. Basically, the author maintains that this paradox can be explained by the small number of events in randomised clinical trials (RCTs) and selection bias in observational studies [1].

First, pneumonia risk is increased in patients with COPD, and chronic treatment with ICS further increases this risk [2, 3]. However, this higher incidence of pneumonia is not uniform in different studies, and in recent RCTs conducted in a large number of patients the incidence of pneumonia was not increased in patients randomised to ICS treatment [4–6]. This suggests that other factors, such as the specific drug, dose and population studied, may affect this risk.

Suissa [1] suggests that ICS-treated patients may develop pneumonia for the same reasons as the rest of COPD patients, and additionally due to factors directly attributable to ICS. Two different concepts used by the author should be clarified: 1) pneumonia mortality (pneumonia deaths/total number of patients), and 2) case fatality (pneumonia deaths/number of patients with pneumonia). Following the same example used in the article, if the risk of pneumonia in ICS users is 2, and the prognosis of severe cases of pneumonia (case fatality) is similar for ICS and non-ICS users, global mortality for pneumonia in ICS users should be 2. Conversely, if pneumonia mortality is similar, the prognosis of severe cases of pneumonia should be 0.5. In our opinion, this option is more realistic since in the meta-analysis conducted by Festic et al. [3] case fatality in observational studies was lower in ICS users (RR 0.7, 95% CI 0.59–0.88).

Secondly, Suissa [1] proposes that the lower mortality for pneumonia observed in these studies can be explained by selection bias. The argument is that this lower mortality in ICS patients may be related to fewer comorbidities or having less severe COPD, among other factors. However, observational studies statistically adjust for many of these possible confounders, and we cannot find any plausible reason to explain why patients not treated with ICS should have more comorbidities or more severe COPD than ICS-treated patients [7].

To avoid this bias Suissa [1] analysed a cohort study defined by ICS exposure at inclusion. In this study, performed between 1998 and 2003, pneumonia mortality was increased in ICS patients. However, global mortality was lower with ICS use, which can lead to a bias (only living patients can die of pneumonia). In subsequent publications, S. Suissa and co-workers confirm that ICS patients had an increased risk of severe pneumonias, but regrettably, the authors did not explore the mortality data in these studies [8, 9].

Finally, the meta-analysis of RCTs referenced in the article showed an increase in pneumonia mortality among patients treated with ICS, though this relationship did not reach statistical significance (RR 1.50, 95% CI 0.85–2.67), and the authors concluded that the risk of pneumonia mortality was not increased in ICS users [3]. Suissa [1] suggests that the reason is the limited number of events. This may be a factor, but the total number of patients included in this meta-analysis is considerable (12 958 patients). Of note, since the publication of this meta-analysis, at least 10 RCTs containing 40 424 COPD patients randomised to ICS treatment have been published (table 1). Of these, in seven (24 811 patients) non-fatal pneumonia cases were reported. We performed a joint analysis of the RCTs included in the meta-analysis of Festic et al. [3] and those published subsequently with a total of 53 940 patients (31 396 ICS and 22 544 non-ICS). In this analysis, mortality from pneumonia was 58/31 396 for ICS users and 33/22 544 for non-ICS. (RR 0.97, 95% CI 0.58–1.60; p=0.89, I2=7.8%). We believe that these data reinforce the notion that pneumonia-related deaths are very infrequent in RCTs and, given the number of patients included, the clinical relevance of ICS in pneumonia mortality is doubtful.

View this table:
  • View inline
  • View popup
TABLE 1

Pneumonia mortality in randomised clinical trials

Certainly, pneumonia is an undesirable event, but the increased risk of pneumonia in COPD patients should be counter-balanced by a decrease in exacerbations, especially the most severe that require hospitalisation, and that lead to an increase in mortality, as Suissa et al. [23] have previously demonstrated.

Therefore, we believe that the conclusion stated by Suissa [1] that: “the evidence is now clear that ICS use is associated with a higher incidence of pneumonia and of pneumonia-related mortality”, is debatable, given available data. The use of ICS should be in accordance with current recommendations, and clinicians must balance the pneumonia risk with the reduction in both severe exacerbations and the mortality.

Shareable PDF

Supplementary Material

This one-page PDF can be shared freely online.

Shareable PDF ERJ-01035-2019.Shareable

Footnotes

  • Conflict of interest: P. Almagro reports grants from AstraZeneca and SEPAR, personal fees from Chiesi, Boehringer Ingelheim and GlaxoSmithKline, travel support from Rovi and Esteve, outside the submitted work.

  • Conflict of interest: P. Martinez-Camblor has nothing to disclose.

  • Conflict of interest: J.B. Soriano reports grants from Linde, travel support from Almirall, AstraZeneca, Boehringer Ingelheim, Chest, Chiesi, ERS, Gebro, Grifols, GSK, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda, outside the submitted work.

  • Received April 11, 2019.
  • Accepted May 30, 2019.
  • Copyright ©ERS 2019
https://www.ersjournals.com/user-licence

References

  1. ↵
    1. Suissa S
    . Inhaled corticosteroids preventing pneumonia mortality: paradox or selection bias? Eur Respir J 2019; 53: 1802112.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Soriano JB,
    2. Visick GT,
    3. Muellerova H, et al.
    Patterns of comorbidities in newly diagnosed COPD and as explained in the study and asthma in primary care. Chest 2005; 128: 2099–2107.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Festic E,
    2. Bansal V,
    3. Gupta E, et al.
    Association of inhaled corticosteroids with incident pneumonia and mortality in COPD patients: systematic review and meta-analysis. COPD 2016; 13: 312–326.
    OpenUrl
  4. ↵
    1. Vestbo J,
    2. Anderson JA,
    3. Brook RD, et al.
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817–1826.
    OpenUrlPubMed
    1. Papi A,
    2. Vestbo J,
    3. Fabbri L, et al.
    Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018; 391: 1076–1084.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ferguson GT,
    2. Rabe KF,
    3. Martinez FJ, et al.
    Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 10: 747–758.
    OpenUrl
  6. ↵
    1. Joo MJ,
    2. Au DH,
    3. Fitzgibbon ML, et al.
    Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104: 246–252.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Suissa S,
    2. Patenaude V,
    3. Lapi F, et al.
    Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68: 1029–1036.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Suissa S,
    2. Dell'Aniello S,
    3. Ernst P
    . Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice. Chest 2019; 155: 1158–1165.
    OpenUrl
    1. Calverley PMA,
    2. Stockley RA,
    3. Seemungal TAR, et al.
    Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505–512.
    OpenUrlCrossRefPubMedWeb of Science
    1. Crim C,
    2. Calverley PM,
    3. Anderson JA, et al.
    Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009; 34: 641–647.
    OpenUrlAbstract/FREE Full Text
    1. Dransfield MT,
    2. Bourbeau J,
    3. Jones PW, et al.
    Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210–223.
    OpenUrl
    1. Kardos P,
    2. Wencker M,
    3. Glaab T, et al.
    Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–149.
    OpenUrlCrossRefPubMedWeb of Science
  9. GlaxoSmithKline. A Randomized, Double-Blind, Parallel-Group Clinical Trial Evaluating the Effect of the Fluticasone Propionate/Salmeterol Combination Product 250/50mcg Twice Daily Via DISKUS® Inhaler Versus Salmeterol 50mcg Twice Daily Via DISKUS® Inhaler on Bone Mineral Density in Subjects With Chronic Obstructive Pulmonary Disease (COPD). https://clinicaltrials.gov/ct2/show/NCT00355342 Date last updated: 2 July 2019.
    1. Sharafkhaneh A,
    2. Southard JG,
    3. Goldman M, et al.
    Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med 2012; 106: 257–268.
    OpenUrlCrossRefPubMed
    1. Ferguson GT,
    2. Tashkin DP,
    3. Skärby T, et al.
    Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med 2017; 132: 31–41.
    OpenUrl
    1. Vestbo J,
    2. Papi A,
    3. Corradi M, et al.
    Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017; 389: 1919–1929.
    OpenUrlCrossRefPubMed
    1. Lipson DA,
    2. Barnhart F,
    3. Brealey N, et al.
    Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018; 378: 1671–1680.
    OpenUrlCrossRefPubMed
    1. Siler TM,
    2. Nagai A,
    3. Scott-Wilson CA, et al.
    A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med 2017; 123: 8–17.
    OpenUrl
    1. Wedzicha JA,
    2. Banerji D,
    3. Chapman KR, et al.
    Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 2016; 374: 2222–2234.
    OpenUrlCrossRefPubMed
    1. Zhong N,
    2. Wang C,
    3. Zhou X, et al.
    LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstrut Pulmon Dis 2015; 10: 1015–1026.
    OpenUrl
    1. Vogelmeier CF,
    2. Bateman ED,
    3. Pallante J, et al.
    Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1: 51–60.
    OpenUrl
  10. ↵
    1. Suissa S,
    2. Dell'Aniello S,
    3. Ernst P
    . Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957–963.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 54 Issue 3 Table of Contents
European Respiratory Journal: 54 (3)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Inhaled corticosteroids and pneumonia mortality in COPD patients
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Inhaled corticosteroids and pneumonia mortality in COPD patients
Pere Almagro, Pablo Martinez-Camblor, Joan B. Soriano
European Respiratory Journal Sep 2019, 54 (3) 1901035; DOI: 10.1183/13993003.01035-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Inhaled corticosteroids and pneumonia mortality in COPD patients
Pere Almagro, Pablo Martinez-Camblor, Joan B. Soriano
European Respiratory Journal Sep 2019, 54 (3) 1901035; DOI: 10.1183/13993003.01035-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Shareable PDF
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Correspondence

  • Treatable traits in ILD: why not consider acute exacerbations?
  • Inclusion of lung health outcomes in TB treatment trials
  • Understanding confounding in Mendelian randomisation studies
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society